TY - JOUR
T1 - Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients With Hepatocellular Carcinoma
AU - Saito, Akihiro
AU - Kikuchi, Masafumi
AU - Matsumoto, Yuko
AU - Sugawara, Erina
AU - Takao, Gesshu
AU - Inomata, Hayato
AU - Takahashi, Akane
AU - Sato, Yuji
AU - Kumondai, Masaki
AU - Sato, Yu
AU - Sato, Toshihiro
AU - Ninomiya, Masashi
AU - Inoue, Jun
AU - Maekawa, Masamitsu
AU - Mano, Nariyasu
N1 - Funding Information:
M. Kikuchi, Y. Sato, T. Sato, M. Maekawa, and N. Mano received research funding from Shimadzu Corporation. Masafumi Kikuchi received JSPS KAKENHI (Grant Number JP21K06708). The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Background:The anticancer drug, Lenvima (lenvatinib), has severe side effects. Therapeutic drug monitoring helps ensure its efficacy and safety. Regular and optimally timed blood sampling is tough, especially when lenvatinib is self-medicated. Microsampling using the easy to handle Microsampling Wing (MSW) may help circumvent this problem. However, current lenvatinib detection methods are not sensitive enough to detect its concentrations in microsamples (<50-250 L). Thus, the aim of this study was 2-fold (1) develop an analytic method to estimate plasma lenvatinib concentrations in microsamples and (2) verify whether this method works on micro (5.6 L) blood plasma samples obtained clinically through MSW from patients with unresectable hepatocellular carcinoma (HCC).Methods:A simple, highly sensitive, and specific liquid chromatography-electrospray ionization tandem mass spectrometry method was developed. Using this novel protocol, the trough blood plasma concentration of lenvatinib was measured for both blood sampled conventionally and that using MSW. Thirty-five venous whole blood samples were obtained from 11 patients with HCC. Furthermore, the stability of lenvatinib in MSW samples during storage was evaluated.Results:The mean plasma lenvatinib concentration estimates were not significantly different between the MSW and conventional venous blood samples. CV for interday and intraday assays was low. Up to day 5, the lenvatinib concentration in the MSW samples was 85%-115% of the initial day concentration (when stored at 25°C or 4°C). The interference of endogenous matrix components in the human plasma was low.Conclusions:These results indicate that the novel mass spectrometry protocol accurately measures lenvatinib in human plasma and is reproducible. Thus, MSW could be a useful microsampling device for lenvatinib therapeutic drug monitoring in patients with HCC when used in combination with this novel liquid chromatography-electrospray ionization tandem mass spectrometry detection method.
AB - Background:The anticancer drug, Lenvima (lenvatinib), has severe side effects. Therapeutic drug monitoring helps ensure its efficacy and safety. Regular and optimally timed blood sampling is tough, especially when lenvatinib is self-medicated. Microsampling using the easy to handle Microsampling Wing (MSW) may help circumvent this problem. However, current lenvatinib detection methods are not sensitive enough to detect its concentrations in microsamples (<50-250 L). Thus, the aim of this study was 2-fold (1) develop an analytic method to estimate plasma lenvatinib concentrations in microsamples and (2) verify whether this method works on micro (5.6 L) blood plasma samples obtained clinically through MSW from patients with unresectable hepatocellular carcinoma (HCC).Methods:A simple, highly sensitive, and specific liquid chromatography-electrospray ionization tandem mass spectrometry method was developed. Using this novel protocol, the trough blood plasma concentration of lenvatinib was measured for both blood sampled conventionally and that using MSW. Thirty-five venous whole blood samples were obtained from 11 patients with HCC. Furthermore, the stability of lenvatinib in MSW samples during storage was evaluated.Results:The mean plasma lenvatinib concentration estimates were not significantly different between the MSW and conventional venous blood samples. CV for interday and intraday assays was low. Up to day 5, the lenvatinib concentration in the MSW samples was 85%-115% of the initial day concentration (when stored at 25°C or 4°C). The interference of endogenous matrix components in the human plasma was low.Conclusions:These results indicate that the novel mass spectrometry protocol accurately measures lenvatinib in human plasma and is reproducible. Thus, MSW could be a useful microsampling device for lenvatinib therapeutic drug monitoring in patients with HCC when used in combination with this novel liquid chromatography-electrospray ionization tandem mass spectrometry detection method.
KW - LC/ESI-MS/MS
KW - Microsampling Wing
KW - lenvatinib
KW - microsampling
KW - therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=85141935414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141935414&partnerID=8YFLogxK
U2 - 10.1097/FTD.0000000000001013
DO - 10.1097/FTD.0000000000001013
M3 - Article
C2 - 35863065
AN - SCOPUS:85141935414
SN - 0163-4356
VL - 44
SP - 771
EP - 776
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 6
ER -